Literature DB >> 29102950

Fibrotic Lung Toxicity Induced by Hydroxycarbamide.

Elena Bargagli1, Marco Palazzi2, Francesco Perri2, Elena Torricelli2, Elisabetta Rosi2, Alessandra Bindi3, Massimo Pistolesi2, Luca Voltolini4.   

Abstract

A patient treated for 4 months with hydroxycarbamide (hydroxyurea) for chronic myelomonocytic leukemia was admitted to hospital for recently developed severe dyspnea and acute respiratory failure. The computed tomographic scan of the chest showed diffuse ground glass opacities, some centrilobular low-density nodules (resembling hypersensitivity pneumonitis-like pattern), and minimal interstitial reticulation of the subpleural region. The analysis of bronchoalveolar lavage fluid excluded infection, as did serological examinations. The patient was started on oxygen therapy and with relief of thrombocytopenia and suspected hemolytic anemia, hydroxyurea treatment was discontinued. The patient underwent steroid therapy, with a rapid progressive improvement of clinical and radiological features. As hydroxyurea is increasingly used for a number of systemic disorders, physicians must be aware of its potential lung toxicity, requiring immediate cessation of the treatment and empiric corticosteroid therapy. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Hydroxycarbamide; case report; hydroxyurea; interstitial pneumonitis; lung toxicity

Mesh:

Substances:

Year:  2017        PMID: 29102950      PMCID: PMC5756656          DOI: 10.21873/invivo.11194

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  17 in total

1.  A 62-year-old woman with dyspnea, leukocytosis, and diffuse ground-glass opacities.

Authors:  Abubakr A Bajwa; Faisal Usman; David Wolfson; Luis F Laos; James D Cury
Journal:  Chest       Date:  2010-06       Impact factor: 9.410

2.  Dyspnea secondary to pulmonary hematopoiesis as presenting symptom of myelofibrosis with myeloid metaplasia.

Authors:  Elisa Rumi; Francesco Passamonti; Emanuela Boveri; Mara De Amici; Cesare Astori; Marta Braschi; Carlo Castagnola; Umberto Magrini; Mario Cazzola; Mario Lazzarino
Journal:  Am J Hematol       Date:  2006-02       Impact factor: 10.047

3.  Hydroxycarbamide-induced pneumonitis.

Authors:  Peh Sun Loo; Mohammed Khan; Graeme P Currie; Ehab Husain; Keith M Kerr
Journal:  Histopathology       Date:  2009-08       Impact factor: 5.087

4.  Hydroxyurea-induced interstitial pneumonitis: case report and review of the literature.

Authors:  M Internullo; V Giannelli; L Sardo; C Antonaglia; T Villani; E Angelici; P Palange
Journal:  Eur Rev Med Pharmacol Sci       Date:  2014       Impact factor: 3.507

5.  Drug-induced lung disease: high-resolution CT and histological findings.

Authors:  Joanne R Cleverley; Nicholas J Screaton; Melanie P Hiorns; Julia D A Flint; Nestor L Müller
Journal:  Clin Radiol       Date:  2002-04       Impact factor: 2.350

Review 6.  Hydroxyurea-induced hypersensitivity pneumonitis: A case report and literature review.

Authors:  H S Sandhu; P J Barnes; P Hernandez
Journal:  Can Respir J       Date:  2000 Nov-Dec       Impact factor: 2.409

7.  Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.

Authors:  S Cortelazzo; G Finazzi; M Ruggeri; O Vestri; M Galli; F Rodeghiero; T Barbui
Journal:  N Engl J Med       Date:  1995-04-27       Impact factor: 91.245

8.  Acute alveolitis induced by hydroxyurea in a patient with myeloproliferative syndrome.

Authors:  B Hennemann; K J Bross; A Reichle; R Andreesen
Journal:  Ann Hematol       Date:  1993-09       Impact factor: 3.673

9.  Hydroxyurea-induced Pneumonitis in a Patient with Chronic Myelomonocytic Leukemia: An Autopsy Case.

Authors:  Hisao Imai; Nozomi Matsumura; Yuichi Yamazaki; Yuki Kanayama; Tomomi Masuda; Tomohito Kuwako; Yosuke Kamide; Taku Tomizawa; Shunichi Matsumoto; Takeki Mitsui; Kyoichi Kaira; Akihiro Ono; Yasuhiko Koga; Nobuyuki Shibusawa; Noriaki Sunaga; Takeshi Hisada; Hideaki Yokoo; Masanobu Yamada
Journal:  Intern Med       Date:  2015-12-15       Impact factor: 1.271

Review 10.  Hydroxyurea (hydroxycarbamide) for sickle cell disease.

Authors:  Sarah J Nevitt; Ashley P Jones; Jo Howard
Journal:  Cochrane Database Syst Rev       Date:  2017-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.